Article
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2018
McCoach Caroline E, Le Anh T, Gowan Katherine, Jones Kenneth, Schubert Laura, Doak Andrea, Estrada-Bernal Adriana, Davies Kurtis D, Merrick Daniel T, Bunn Paul A, Purcell W Tom, Dziadziuszko Rafal, Varella-Garcia Marileila, Aisner Dara L, Camidge D Ross, Doebele Robert C
Abstract excerpt
Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non-small cell lung cancer (NSCLC) harboring ALK (ALK+) and ROS1 (ROS1+) gene fusions ultimately progress. Here, we report on the potential resistance mechanisms in a series of patients with ALK+ and ROS1+ NSCLC progressing on different types and/or lines of ROS1/ALK-targeted therapy.Experimental Design: We used a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.